{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T18:55:45Z","timestamp":1779216945071,"version":"3.51.4"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":109,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine Case Reports"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.rmcr.2026.102421","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T16:13:11Z","timestamp":1776787991000},"page":"102421","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Severe psoriasis as an immune-related adverse event after long-term atezolizumab therapy for pulmonary large-cell neuroendocrine carcinoma: A case report"],"prefix":"10.1016","volume":"61","author":[{"given":"Chisa","family":"Murayama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Ikezawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chihiro","family":"Shiiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Oda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Ikezawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Matsunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuaki","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Furuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Kitai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Sakakibara-Konishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Konno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmcr.2026.102421_bib1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejca.2020.04.025","article-title":"Late immune-related adverse events in long-term responders to PD-1\/PD-L1 checkpoint inhibitors: a multicentre study","volume":"134","author":"Nigro","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.rmcr.2026.102421_bib2","doi-asserted-by":"crossref","first-page":"382","DOI":"10.5114\/ada.2018.80272","article-title":"Principles of prophylactic and therapeutic management of skin toxicity during treatment with checkpoint inhibitors","volume":"36","author":"Kami\u0144ska-Winciorek","year":"2019","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.rmcr.2026.102421_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.2668","article-title":"Late-onset immune-related adverse events after immne checkpoint inhibitor therapy","volume":"8","author":"Durbin","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.rmcr.2026.102421_bib4","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.rmcr.2026.102421_bib5","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmcr.2026.102421_bib6","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1200\/JCO.2015.63.7421","article-title":"Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study","volume":"34","author":"McDermott","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.rmcr.2026.102421_bib7","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2147\/DDDT.S188893","article-title":"Safety and efficacy of atezolizumab in the treatment of cancers: a systematic review and pooled-analysis","volume":"13","author":"Tie","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.rmcr.2026.102421_bib8","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jaad.2020.08.137","article-title":"Immune checkpoint-mediated psoriasis: a multicenter European study of 115 patients from the European network for cutaneous adverse event to oncologic drugs (ENCADO) group","volume":"84","author":"Nikolaou","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.rmcr.2026.102421_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jamadermatol.2024.4129","article-title":"Psoriasis risk with immune checkpoint inhibitors","volume":"161","author":"To","year":"2025","journal-title":"JAMA Dermatol."}],"container-title":["Respiratory Medicine Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007126000584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007126000584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T07:26:53Z","timestamp":1779002813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213007126000584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":9,"alternative-id":["S2213007126000584"],"URL":"https:\/\/doi.org\/10.1016\/j.rmcr.2026.102421","relation":{},"ISSN":["2213-0071"],"issn-type":[{"value":"2213-0071","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe psoriasis as an immune-related adverse event after long-term atezolizumab therapy for pulmonary large-cell neuroendocrine carcinoma: A case report","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmcr.2026.102421","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102421"}}